The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 25901531 |
211 |
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. |
Sloan-Kettering Institute For Cancer Research |
| 24673104 |
185 |
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease. |
Vertex Pharmaceuticals |
| 24332488 |
11 |
Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases. |
Vertex Pharmaceuticals |
| 23965125 |
26 |
Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. |
Memorial Sloan-Kettering Cancer Center |
| 22938030 |
22 |
EC144 is a potent inhibitor of the heat shock protein 90. |
Biogen Idec |
| 20055425 |
29 |
Heat shock protein 90: inhibitors in clinical trials. |
Biogen Idec |
| 28816449 |
14 |
Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors. |
Ulsan National Institutes Of Science And Technology (Unist) |
Search and Browse
